Departament of Gastroenterology, Liver Unit, Hospital Universitari Germans Trias i Pujol, Spain.
J Clin Gastroenterol. 2011 Nov-Dec;45(10):906-11. doi: 10.1097/MCG.0b013e3182284e13.
Prognosis of decompensated alcoholic cirrhosis is based mainly on studies that included patients with different severities of liver disease and did not recognize either hepatitis C virus epidemic or changes in clinical management of cirrhosis.
To define the long-term course after the first hepatic decompensation in alcoholic cirrhosis.
Prospective inclusion at the start point of decompensated cirrhosis of 165 consecutive patients with alcoholic cirrhosis without known hepatocellular carcinoma hospitalized from January 1998 to December 2001 was made. Follow-up was maintained until death or the end of the observation period (April 1, 2010).
The patients were followed for 835.75 patient years. Median age was 56 years (95% confidence interval: 54-58). Baseline Child-Pugh score was 9 (95% CI: 8-9), and model for end-stage liver disease (MELD) was 13.8 (95% CI: 12.5-14.7). Ascites was the most frequent first decompensation (51%). During follow-up, 99 (60%) patients were abstinent, hepatocellular carcinoma developed in 18 (11%) patients, and 116 patients died (70%). Median overall survival was 61 months (95% CI: 48-74). Median survival probability after onset of hepatic encephalopathy (HE) was only 14 months (95% CI: 5-23). Age, baseline MELD, albumin, development of HE, and persistence of alcohol use were independently correlated with mortality.
Patients with alcoholic cirrhosis show a high frequency of complications. The low mortality rate in our cohort of patients probably reflects the improvement in the management of patients with cirrhosis; it is mainly influenced by baseline MELD, age, HE development, and continued abstinence. Patients who develop HE should be considered for hepatic transplantation.
失代偿期酒精性肝硬化的预后主要基于包括不同严重程度肝病患者的研究,且这些研究未识别丙型肝炎病毒流行或肝硬化临床管理的变化。
明确酒精性肝硬化首次肝性失代偿后的长期病程。
前瞻性纳入 1998 年 1 月至 2001 年 12 月住院的 165 例无已知肝细胞癌的酒精性肝硬化失代偿期患者。随访至死亡或观察期结束(2010 年 4 月 1 日)。
患者的中位随访时间为 835.75 患者年。中位年龄为 56 岁(95%可信区间:54-58)。基线时 Child-Pugh 评分为 9(95%可信区间:8-9),终末期肝病模型(MELD)为 13.8(95%可信区间:12.5-14.7)。腹水是最常见的首次失代偿(51%)。随访期间,99 例(60%)患者戒酒,18 例(11%)患者发生肝细胞癌,116 例患者死亡(70%)。中位总生存期为 61 个月(95%可信区间:48-74)。肝性脑病(HE)发生后中位生存时间仅为 14 个月(95%可信区间:5-23)。年龄、基线 MELD、白蛋白、HE 发生和持续饮酒与死亡率独立相关。
酒精性肝硬化患者常发生并发症。本队列患者的低死亡率可能反映了对肝硬化患者管理的改善;主要受基线 MELD、年龄、HE 发生和持续戒酒的影响。发生 HE 的患者应考虑肝移植。